Core Insights - Calidi Biotherapeutics is hosting a webinar on July 24, 2025, to discuss its innovative approach to precision genetic medicine using its proprietary RedTail™ platform [1][2] - The RedTail platform is designed to deliver genetic therapies to difficult-to-treat tumors while evading immune detection, showcasing promising preclinical data [2][5] - The oncology market is projected to exceed $560 billion by 2033, presenting significant growth opportunities for Calidi [2] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for delivering genetic medicines to disease sites [5][6] - The RedTail platform has been developed over a decade and utilizes engineered viral vectors to effectively reach tumor sites and deliver gene therapies [5][6] - The lead candidate, CLD-401, is currently in IND-enabling studies and targets non-small cell lung cancer, ovarian cancer, and other high unmet medical need tumor types [6] Strategic Initiatives - The company is advancing towards IND filing and exploring strategic partnerships with pharmaceutical companies for global commercialization [2] - Calidi's business model is capital-efficient, with a strong balance sheet and a next-generation pipeline targeting both cancer and autoimmune diseases [2]